BioTech Blogs and Articles

Eli Lilly Announces Positive Results for Treating Crohn’s Disease with Omvoh
BlogFeb 19, 2026

Eli Lilly Announces Positive Results for Treating Crohn’s Disease with Omvoh

Eli Lilly reported that its biologic Omvoh (mirikizumab) sustained steroid‑free remission for three years in Crohn’s disease patients in the Phase 3 VIVID‑2 open‑label extension study. More than 90% of participants remained in remission, with 80% experiencing relief from bowel urgency. The...

By Pharmaceutical Executive (independent trade outlet)
IL-6 as a Measure of Peripheral Inflammation Is More Often Elevated in Cognitively Impaired Individuals
BlogFeb 19, 2026

IL-6 as a Measure of Peripheral Inflammation Is More Often Elevated in Cognitively Impaired Individuals

A recent open‑access study of 514 Canadian seniors examined peripheral inflammation using IL‑6 and C‑reactive protein. The analysis revealed that elevated IL‑6 levels were present in 12% of cognitively normal participants but rose sharply to 36‑55% among Alzheimer’s, mixed dementia,...

By Fight Aging!
From Skin Biopsy to iPS Cell Proposals: Emails Involving George Church’s Personal Genome Project and Jeffrey Epstein
BlogFeb 19, 2026

From Skin Biopsy to iPS Cell Proposals: Emails Involving George Church’s Personal Genome Project and Jeffrey Epstein

Recent court‑released Epstein files contain emails that link Harvard professor George Church’s Personal Genome Project to Jeffrey Epstein. The correspondence documents a skin‑biopsy taken from Epstein, proposals to generate induced pluripotent stem (iPS) cells, and even CRISPR editing ideas, with...

By The Niche
A Circulating Inflammation Suppressor Decreases Mortality
BlogFeb 19, 2026

A Circulating Inflammation Suppressor Decreases Mortality

Researchers used Mendelian randomization to demonstrate that the inflammatory cytokine IL6 directly increases all‑cause mortality, while its soluble receptor IL6R has the opposite effect. Elevated circulating IL6R was linked to lower risk of lung cancer, diabetes, stroke and coronary artery...

By SENS Research Foundation – The SENSible Blog
Tradipitant
BlogFeb 19, 2026

Tradipitant

Vanda Pharmaceuticals received FDA approval for tradipitant (Nereus®), an oral selective NK1 receptor antagonist, to treat motion‑induced nausea and vomiting. The approval marks the first new drug for motion sickness in more than four decades, highlighting a significant regulatory milestone....

By Drug Hunter
FNIH Biomarkers Consortium Study Shows “Clock Model” Blood Test Can Predict Onset of Alzheimer’s Symptoms Years in Advance
BlogFeb 19, 2026

FNIH Biomarkers Consortium Study Shows “Clock Model” Blood Test Can Predict Onset of Alzheimer’s Symptoms Years in Advance

The FNIH Biomarkers Consortium unveiled a “clock model” that uses a single blood test to forecast Alzheimer’s disease symptom onset 3‑4 years before clinical presentation. The model aggregates plasma biomarkers into a temporal trajectory, and a new web‑based visualization tool...

By HealthTech HotSpot
Oral Nanozyme Treats Colitis-Linked Mental Disorders via Gut-Brain Axis
BlogFeb 19, 2026

Oral Nanozyme Treats Colitis-Linked Mental Disorders via Gut-Brain Axis

Researchers at Yangzhou and Nanjing Universities have created an oral polysaccharide‑engineered nanozyme—fucoidan‑cerium nanocomplexes (FucCeNCs)—to treat colitis‑associated anxiety and depression. The nanocomplex combines cerium’s superoxide dismutase‑like activity with fucoidan’s prebiotic properties, enabling simultaneous reactive oxygen/nitrogen species scavenging and gut microbiota modulation....

By Nanowerk
Partial Reprogramming of Neurons Encoding Memory Improves Cognitive Function in Aged Mice
BlogFeb 19, 2026

Partial Reprogramming of Neurons Encoding Memory Improves Cognitive Function in Aged Mice

Researchers applied cyclic OSK (Oct4‑Sox2‑Klf4) gene therapy to memory‑encoding neurons in aged mice, achieving partial cellular reprogramming without full pluripotency. The intervention reversed senescence‑related gene expression, restored youthful epigenetic patterns, and normalized synaptic plasticity in both hippocampal and prefrontal engrams....

By Fight Aging!
Pharma Pulse: FDA’s Moderna Reversal and Eli Lilly’s $100 Million IL-6 Bet
BlogFeb 19, 2026

Pharma Pulse: FDA’s Moderna Reversal and Eli Lilly’s $100 Million IL-6 Bet

The FDA has reversed its earlier refusal-to-file and will review Moderna’s seasonal mRNA influenza vaccine, with a decision slated for August 5, 2026. Moderna now seeks full approval for adults aged 50‑64 and accelerated approval for those 65 and older. Meanwhile, Eli Lilly...

By Pharmaceutical Commerce (independent trade)
Antioxidant Nanoparticles May Protect Male Fertility During Chemotherapy
BlogFeb 19, 2026

Antioxidant Nanoparticles May Protect Male Fertility During Chemotherapy

A preclinical study published in Reproductive and Developmental Medicine found that combining melatonin with zinc oxide nanoparticles mitigates cyclophosphamide‑induced reproductive toxicity in male rats. The antioxidant duo restored testosterone and luteinizing hormone levels, lowered oxidative stress markers, and preserved spermatogenic...

By BioTechniques (independent journal site)
UV Red Flag: Color-Changing ‘Living’ Material Warns of Harmful Radiation
BlogFeb 19, 2026

UV Red Flag: Color-Changing ‘Living’ Material Warns of Harmful Radiation

Researchers at the Technical University of Munich have created a bio‑hybrid coating that visibly signals UV‑A exposure by turning from green to red. The sensor embeds dry Escherichia coli cells loaded with the photoconvertible protein mEosFP, which undergoes an irreversible...

By BioTechniques (independent journal site)
Genentech’s Fenebrutinib Yields Positive Results in Phase III MS Trial
BlogFeb 18, 2026

Genentech’s Fenebrutinib Yields Positive Results in Phase III MS Trial

Genentech’s oral BTK inhibitor fenebrutinib met its primary endpoint in the Phase III FENtrepid trial for primary progressive multiple sclerosis, showing non‑inferiority to Ocrevus and a 12% risk reduction in confirmed disability progression. The drug also delivered a 26% lower risk...

By Xtalks – Biotech Blogs
Anti-Aging Gene Therapy in Alzheimer’s and ALS with Klotho Neurosciences’ Dr. Joseph Sinkule — Episode 243
BlogFeb 18, 2026

Anti-Aging Gene Therapy in Alzheimer’s and ALS with Klotho Neurosciences’ Dr. Joseph Sinkule — Episode 243

The Xtalks Life Science Podcast featured Joseph Sinkule, CEO of Klotho Neurosciences, discussing the company’s secreted α‑Klotho gene therapy platform aimed at age‑related neurodegenerative diseases such as Alzheimer’s, ALS and Parkinson’s. Klotho leverages a patented anti‑aging gene to develop cell‑ and...

By Xtalks – Biotech Blogs
Reduced APOE Expression Improves Bone Regeneration in Aged Mice
BlogFeb 18, 2026

Reduced APOE Expression Improves Bone Regeneration in Aged Mice

Researchers discovered that elevated circulating APOE in older mice suppresses bone regeneration by inhibiting osteoblast differentiation. Liver‑specific knockout of APOE or a single dose of a neutralizing antibody lowered serum APOE, restored Wnt/β‑catenin signaling, and markedly improved fracture callus density...

By Fight Aging!
Aceclidine
BlogFeb 18, 2026

Aceclidine

Aceclidine (Vizz®) received FDA approval in 2025 as an ophthalmic solution for presbyopia, targeting age‑related near‑vision loss. The drug acts as a pupil‑selective muscarinic agonist, inducing miosis without significant ciliary muscle activity, thereby enhancing depth of focus through a pinhole...

By Drug Hunter
Global Conference to Tackle Longevity Clinical Translation
BlogFeb 18, 2026

Global Conference to Tackle Longevity Clinical Translation

The National University of Singapore Academy for Healthy Longevity is hosting the Geromedicine Conference on February 26-27, 2026, bringing together geroscience researchers, clinicians, and industry leaders. The event emphasizes clinical translation of molecules such as NAD+ precursors, urolithin A, and ergothioneine,...

By SENS Research Foundation – The SENSible Blog
How Does Cholera Colonize the Gut? Unmasking Virulence Activation with Cryo-EM
BlogFeb 18, 2026

How Does Cholera Colonize the Gut? Unmasking Virulence Activation with Cryo-EM

Cryogenic electron microscopy enabled researchers to solve five structures of Vibrio cholerae transcription activation complexes, revealing how the bacterium initiates virulence in the human gut. The study shows ToxR and TcpP transcription factors bind the RNA polymerase α‑C‑terminal domain via...

By BioTechniques (independent journal site)
Global Genomics: Representative Research Is Key to Unlocking the Full Potential of Precision Medicine
BlogFeb 18, 2026

Global Genomics: Representative Research Is Key to Unlocking the Full Potential of Precision Medicine

Professor Segun Fatumo highlights the stark under‑representation of African genomes in global research, where over 86% of GWAS participants are of European ancestry despite Africa housing the greatest genetic diversity. He explains how this gap limits the accuracy of polygenic...

By BioTechniques (independent journal site)
IRF7 Expression Drives Instability in Atherosclerotic Plaques
BlogFeb 18, 2026

IRF7 Expression Drives Instability in Atherosclerotic Plaques

Researchers identified interferon regulatory factor 7 (IRF7) as a master transcriptional driver that pushes vascular smooth muscle cells (SMCs) into a pro‑inflammatory, macrophage‑like state, a key step in plaque destabilisation. Single‑cell RNA sequencing and trajectory analysis uncovered an intermediate stem‑endothelial‑monocyte...

By Fight Aging!
The Biotech Bi-Weekly: A 48-Channel SPR Platform, Robust RNA-Seq Libraries and Microgravitational Discoveries
BlogFeb 18, 2026

The Biotech Bi-Weekly: A 48-Channel SPR Platform, Robust RNA-Seq Libraries and Microgravitational Discoveries

Carterra unveiled Vega, the industry’s first 48‑channel high‑throughput SPR platform, delivering roughly 12‑fold higher screening capacity for small‑ and large‑molecule drug candidates. Covaris introduced the truCOVER® Total RNA Library Prep Kit, enabling robust RNA‑seq libraries from as little as 10 ng...

By BioTechniques (independent journal site)
Nanoparticle-Based Gene Editing Could Expand Treatment Options for Cystic Fibrosis
BlogFeb 18, 2026

Nanoparticle-Based Gene Editing Could Expand Treatment Options for Cystic Fibrosis

UCLA researchers have engineered lipid nanoparticles to co‑deliver CRISPR/Cas9 components and a full‑length CFTR gene, achieving precise, mutation‑agnostic insertion in human airway cells. The non‑viral system corrected 3‑4% of cells yet restored up to 100% of normal chloride channel function,...

By Nanowerk
Injectable Nanocomposite Hemostat Speeds Blood Clotting for Trauma Care
BlogFeb 18, 2026

Injectable Nanocomposite Hemostat Speeds Blood Clotting for Trauma Care

Researchers at Texas A&M have created injectable nanocomposite hemostats that cut blood clotting time from six‑seven minutes to one‑two minutes, slashing bleeding duration by up to 70% in internal hemorrhage models. The devices combine clay‑derived nanosilicates with a shape‑memory foam...

By Nanowerk
What the Folinic Acid Retraction Means for Autism Treatment
BlogFeb 17, 2026

What the Folinic Acid Retraction Means for Autism Treatment

The European Journal of Pediatrics retracted the 2024 randomized trial that claimed folinic acid reduced autism symptoms, citing data that did not support its conclusions. The study had been the largest of its kind, influencing clinical recommendations and regulatory guidance....

By KevinMD
Key Obstacle to Integrated Bioelectronic Implants Removed with Use of Solid-State Hydrogel
BlogFeb 17, 2026

Key Obstacle to Integrated Bioelectronic Implants Removed with Use of Solid-State Hydrogel

Swedish researchers have created a photo‑patternable solid‑state hydrogel electrolyte using i‑carrageenan and PEGDA, achieving ionic conductivity above 10 mS cm⁻¹ and feature sizes down to 15 µm. The material replaces liquid electrolytes in organic electrochemical transistors (OECTs), enabling fast, dense, and flexible circuits...

By FrogHeart
The Aging of Retinal Vasculature Reflects the Aging of the Brain
BlogFeb 17, 2026

The Aging of Retinal Vasculature Reflects the Aging of the Brain

Researchers used UK Biobank data to map vascular phenotypes across the retina, carotid artery, aorta, and brain, revealing consistent cross‑organ correlations. Retinal vascular density showed modest but significant negative links with white‑matter hyperintensities, carotid intima‑media thickness, and aortic lumen size,...

By Fight Aging!
The Payload Paradox: Why the Obsession with Potency May Be Holding the ADC Field Back
BlogFeb 17, 2026

The Payload Paradox: Why the Obsession with Potency May Be Holding the ADC Field Back

A European biotech is challenging the ADC status quo by prioritising novel targets and payloads over sheer potency. In an interview, the company’s CSO argues that the industry’s obsession with ultra‑potent cytotoxins like MMAE and DM1 is stalling progress, creating...

By Biotech Strategy Blog
Safer CNS Drugs with BrainOnly Pharmacology
BlogFeb 17, 2026

Safer CNS Drugs with BrainOnly Pharmacology

The article outlines a growing strategy to develop central nervous system (CNS) therapeutics that remain pharmacologically active only within the brain, termed "BrainOnly" pharmacology. By leveraging selective transport mechanisms, pro‑drug designs, and peripheral clearance pathways, researchers aim to minimize off‑target...

By Drug Hunter
Free Access to Single-Cell Long-Read mRNA Sequencing Tech with New Grant
BlogFeb 17, 2026

Free Access to Single-Cell Long-Read mRNA Sequencing Tech with New Grant

ArgenTag, now a PacBio Compatible Partner, has launched a grant that provides free access to its Single‑Cell RNA Library Kit for Long‑Read Sequencing. The kit uses a gravity‑based microfluidic chip to isolate individual cells, capture full‑length mRNA, and prepare barcoded...

By BioTechniques (independent journal site)
Rare Disease Month Developments, Part 1 – The Good: RPD PRV Program Renewed, FDA Rare Disease Hub’s 2026 Strategic Agenda...
BlogFeb 17, 2026

Rare Disease Month Developments, Part 1 – The Good: RPD PRV Program Renewed, FDA Rare Disease Hub’s 2026 Strategic Agenda...

Congress renewed the Rare Pediatric Disease Priority Review Voucher (RPD PRV) program, extending it to September 30 2029 and eliminating the dual sunset dates. The FDA released its Rare Disease Innovation Hub’s 2026 Strategic Agenda, allocating $1 million in funding and outlining plans...

By FDA Law Blog
MRNA-Packed Nanoparticles Restore Fertility in Genetically Infertile Mice and Produce Live Offspring
BlogFeb 16, 2026

MRNA-Packed Nanoparticles Restore Fertility in Genetically Infertile Mice and Produce Live Offspring

Researchers at Shanghai Jiao Tong University engineered a lipid nanoparticle (LNP) formulation that delivers therapeutic mRNA directly to spermatocytes in mice. By injecting mRNA encoding the wild‑type Msh5 gene, they transiently restored meiosis in mice with a genetic block, achieving...

By Nanowerk
People Are Still Working on the Senolytic Peptide FOXO4-DRI
BlogFeb 16, 2026

People Are Still Working on the Senolytic Peptide FOXO4-DRI

FOXO4‑DRI, a peptide that blocks the FOXO4‑p53 interaction, continues to be explored as a senolytic therapy. Recent preclinical work shows that injecting the peptide into aged and progeroid mice reduces endothelial cell senescence and improves aortic function. Companies such as...

By Fight Aging!
Silencing Growth Hormone Has Strong Effects in Mouse Brains
BlogFeb 16, 2026

Silencing Growth Hormone Has Strong Effects in Mouse Brains

Researchers engineered mice lacking growth hormone receptors specifically in adipose tissue (Ad‑GHRKO) and observed striking brain benefits in aged males. Compared with control mice, the Ad‑GHRKO group showed increased neuronal activity, reduced neuroinflammation, lower tau phosphorylation, and fewer senescence markers....

By SENS Research Foundation – The SENSible Blog
3D Fragments vs the Histamine H1 Receptor
BlogFeb 16, 2026

3D Fragments vs the Histamine H1 Receptor

Researchers at Vrije Universiteit Amsterdam built an 80‑compound, three‑dimensional fragment library and screened it against the histamine H1 receptor. Only one fragment (1a) showed activity, but iterative optimization yielded the low‑nanomolar antagonist VUF26691 with picomolar cellular potency. The campaign required...

By Practical Fragments
Making a MASH Hit: PNPLA3 and the Rise of Genotype-Driven Therapies
BlogFeb 16, 2026

Making a MASH Hit: PNPLA3 and the Rise of Genotype-Driven Therapies

The lipid serine hydrolase PNPLA3, especially its I148M mutant, has emerged as a genetically validated driver of MASLD/MASH, prompting a wave of genotype‑focused drug programs. RNA‑based modalities—Arrowhead’s GalNAc‑siRNA ARO‑PNPLA3 and AstraZeneca/Ionis’ GalNAc‑ASO AZD2693—are in clinical trials aiming to lower mutant...

By Drug Hunter
Increased O-GlcNAc Transferase Expression as an Approach to Improving Function in the Aging Brain
BlogFeb 16, 2026

Increased O-GlcNAc Transferase Expression as an Approach to Improving Function in the Aging Brain

Age‑related decline in O‑GlcNAc Transferase (OGT) activity contributes to neurodegenerative disorders such as Alzheimer’s, Parkinson’s and ALS. Traditional approaches aim to raise O‑GlcNAc levels by inhibiting O‑GlcNAcase, but recent research highlights transcriptional control of OGT as a more direct therapeutic...

By Fight Aging!
Inflammatory Glycogen Produced by Gut Microbes Contributes to Neurodegeneration
BlogFeb 16, 2026

Inflammatory Glycogen Produced by Gut Microbes Contributes to Neurodegeneration

Researchers have identified inflammatory glycogen produced by gut microbes as a driver of age‑related neurodegeneration, especially in ALS and frontotemporal dementia linked to C9ORF72 mutations. In germ‑free mice lacking C9ORF72, colonization with glycogen‑producing Parabacteroides merdae triggered monocytosis, blood‑brain barrier breakdown,...

By Fight Aging!
Nanopillar-Studded Plastic Films Physically Destroy Viruses, Cutting Infectivity by 94% without Chemicals
BlogFeb 15, 2026

Nanopillar-Studded Plastic Films Physically Destroy Viruses, Cutting Infectivity by 94% without Chemicals

Researchers at RMIT and international partners engineered flexible acrylic films stamped with dense nanopillar arrays using ultraviolet nano‑imprint lithography. The 60 nm pitch configuration reduced human parainfluenza virus type 3 infectivity by up to 94 % within one hour, achieving mechanical rupture of...

By Nanowerk
DNA Nanomachine Inside Living Cells Measures How Aggressive a Cancer Is
BlogFeb 14, 2026

DNA Nanomachine Inside Living Cells Measures How Aggressive a Cancer Is

Researchers at Wenzhou and Fuzhou Universities unveiled a three‑wheel DNA nanomachine (TW‑harvester) that rides a gold‑nanoparticle track inside living tumor cells. The device uses a DNA tetrahedron with an aptamer targeting nucleolin and miR‑21‑triggered wheel activation to cleave fluorescent substrates,...

By Nanowerk
New Fluorescence Strategy Could Enable Real-Time Tracking of Microplastics Inside Living Organisms
BlogFeb 14, 2026

New Fluorescence Strategy Could Enable Real-Time Tracking of Microplastics Inside Living Organisms

Researchers have devised a fluorescence‑monomer synthesis that embeds light‑emitting units directly into microplastic polymers, allowing stable, real‑time imaging of particles inside living organisms. Current detection methods provide only static snapshots and require destructive sampling, limiting insight into particle transport, transformation,...

By Nanowerk
Longevity Innovation Forum in San Diego
BlogFeb 13, 2026

Longevity Innovation Forum in San Diego

Longevity Global is launching the inaugural Longevity Innovation Forum in San Diego on March 11‑12, 2026, gathering leading scientists, clinicians, biotech founders and investors to accelerate healthy‑aging research. The two‑day summit features high‑profile speakers such as Mike Snyder, Eric Verdin,...

By SENS Research Foundation – The SENSible Blog
Cellular Reprogramming Rescues Memory-Encoding Neurons
BlogFeb 13, 2026

Cellular Reprogramming Rescues Memory-Encoding Neurons

Scientists at EPFL applied a three‑factor (OSK) partial reprogramming cocktail to memory‑encoding engram neurons in 9‑10‑month‑old mice and Alzheimer’s‑model strains. Using a dual‑AAV system gated by doxycycline, OSK expression was limited to neurons active during a learning event, preserving cell...

By SENS Research Foundation – The SENSible Blog
The FDA:  Promoting Quack Nostrums Based on “Incredible Stories” While Rejecting Vaccines Despite Successful RCTs
BlogFeb 13, 2026

The FDA:  Promoting Quack Nostrums Based on “Incredible Stories” While Rejecting Vaccines Despite Successful RCTs

The U.S. FDA declined to review Moderna's mRNA influenza vaccine, even though two phase‑3 trials involving 43,800 participants demonstrated a 27% efficacy advantage over the standard Fluarix vaccine and a 49% reduction in hospitalizations. FDA officials cited the comparator arm...

By Science-Based Medicine
Organoids and Artificial Intelligence 🫐
BlogFeb 13, 2026

Organoids and Artificial Intelligence 🫐

The episode explores the rapid convergence of organoid technology and artificial intelligence, highlighting how AI-driven image analysis, multidimensional data integration, and high‑throughput screening are transforming organoid research. It introduces the emerging field of Organoid Intelligence, where brain organoids act as...

By Metaphysical Cells
Creating CAR-T Cells Using Current Alzheimer’s Antibodies
BlogFeb 12, 2026

Creating CAR-T Cells Using Current Alzheimer’s Antibodies

Researchers engineered CD4+ T cells with chimeric antigen receptors (CARs) derived from FDA‑approved Alzheimer’s antibodies aducanumab and lecanemab. The lecanemab‑based CAR (Lec28z) selectively bound fibrillar amyloid‑beta and reduced plaque burden in mouse brains, especially when delivered via transient mRNA transfection....

By SENS Research Foundation – The SENSible Blog
FDA OKs Risky, Pioneering OSK Rejuvenation Trial with Sinclair’s ER-100
BlogFeb 11, 2026

FDA OKs Risky, Pioneering OSK Rejuvenation Trial with Sinclair’s ER-100

The U.S. Food and Drug Administration has cleared an investigational new drug application for Life Biosciences' ER‑100, a viral gene‑therapy that delivers inducible Oct‑4, Sox‑2 and Klf‑4 (OSK) to the eye. The first‑in‑human trial will enroll a small cohort of...

By The Niche